Skip to main content

Advertisement

SpringerLink
Log in

The treatment of neuroendocrine tumors with long-acting somatostatin analogs: A single center experience with lanreotide autogel

  • Original Articles
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

The aim of this retrospective study was to evaluate the efficacy, safety, and tolerability of lanreotide autogel given to metastatic well-differentiated (WD) neuroendocrine tumors (NET) patients observed in our Institute between 2005 and 2008. Patients with metastatic NET referred to our tertiary referral center were given lanreotide autogel 120 mg/month by deep sc injection for a period of at least 24 months. The efficacy was evaluated by the relief of disease symptoms, behavior of tumor markers and response rate in terms of time to tumor progression. Safety and tolerability were evaluated by assessing the onset of adverse events and treatment feasibility. Twenty-three patients (13 males), median age 62 yr (range 32–87) were considered for the study. All patients were affected by WD metastatic NET and had tumor progression in the last 6 months before the enrolment in the study. Median duration of response was 28 months (range 6–50 months). Fourteen patients (60.9%) showed flushing and diarrhea which improved by 85.7% and 55.6%, respectively, bronchoconstrinction and abdominal pain also ameliorated. A complete, partial or no-changed response in the tumor markers behavior was observed, respectively, in 42.9%, 22.9%, and 17.1% of cases. According to RECIST (Response Evaluation Criteria In Solid Tumors) criteria (version 1.1), there were 2 partial regression (8.7%) and 15 stable disease (65.3%); 6 patients (26.0%) progressed. No patient complained from any severe adverse reaction. The results of our study suggest that lanreotide autogel is effective in the symptoms, biochemical markers, and tumor progression control of WD metastatic NET and confirm that the treatment is well tolerated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Oberg K, Akerström G, Rindi G, Jelic S; ESMO Guidelines Working Group. Neuroendocrine gastroenteropancreatic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21 (Suppl): v223–7.

    Article  PubMed  Google Scholar 

  2. Oberg K, Hellman P, Kwekkeboom D, Jelic S; ESMO Guidelines Working Group. Neuroendocrine bronchial and thymic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21 (Suppl): v220–2.

    Article  PubMed  Google Scholar 

  3. Boudreaux JP. Surgery for gastroenteropancreatic neuroendocrine tumors (GEPNETS). Endocrinol Metab Clin North Am 2011, 40: 163–71.

    Article  PubMed  Google Scholar 

  4. Joseph S, Wang YZ, Boudreaux JP, et al. Neuroendocrine tumors: current recommendations for diagnosis and surgical management. Endocrinol Metab Clin North Am 2011, 40: 205–31.

    Article  PubMed  Google Scholar 

  5. Steinmüller T, Kianmanesh R, Falconi M, et al.; Frascati Consensus Conference participants. Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2008, 87: 47–62.

    Article  PubMed  Google Scholar 

  6. Oberg K, Ferone D, Kaltsas G, Knigge UP, Taal B, Plöckinger U; Mallorca Consensus Conference participants; European Neuroendocrine Tumor Society. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biotherapy. Neuroendocrinology 2009, 90: 209–13.

    Article  PubMed  Google Scholar 

  7. Eriksson B, Annibale B, Bajetta E, et al; Mallorca Consensus Conference participants; European Neuroendocrine Tumor Society. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: chemotherapy in patients with neuroendocrine tumors. Neuroendocrinology 2009, 90: 214–9.

    Article  CAS  PubMed  Google Scholar 

  8. Raut CP, Kulke MH. Targeted therapy in advanced well-differentiated neuroendocrine tumors. Oncologist 2011, 16: 286–95.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Saltz L, Trochanowski B, Buckley M, et al. Octreotide as an antineoplastic agent in the treatment of functional and non-functional neuroendocrine tumours. Cancer 1993, 72: 244–8.

    Article  CAS  PubMed  Google Scholar 

  10. Arnold R, Trautmann ME, Creutzfeldt W, et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 1996, 38: 430–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  11. Di Bartolomeo M, Bajetta E, Buzzoni R, et al. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer 1996, 77: 402–8.

    Article  PubMed  Google Scholar 

  12. Culler MD, Oberg K, Arnold R, Krenning EP, Sevilla I, Díaz JA. Somatostatin analogs for the treatment of neuroendocrine tumors. Cancer Metastasis Rev 2011, 30 (Suppl): 9–17.

    Article  CAS  PubMed  Google Scholar 

  13. Garland J, Buscombe JR, Bouvier C, et al. Sandostatin LAR (long-acting octreotide acetate) for malignant carcinoid syndrome: a 3-year experience. Aliment Pharmacol Ther 2003, 17: 437–44.

    Article  CAS  PubMed  Google Scholar 

  14. Wymenga AN, Eriksson B, Salmela PI, et al. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumours and hormone-related symptoms. J Clin Oncol 1999, 17: 1111.

    CAS  PubMed  Google Scholar 

  15. Oberg KE, Reubi JC, Kwekkeboom DJ, Krenning EP. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology 2010, 139: 742–53.

    Article  PubMed  Google Scholar 

  16. Clements D, Elias E. Regression of metastatic vipoma with somatostatin analogue SMS 201-995. Lancet 1985, 1: 874–5.

    Article  CAS  PubMed  Google Scholar 

  17. Imtiaz KE, Monteith P, Khaleeli A. Complete histological regression of metastatic carcinoid tumour after treatment with octreotide. Clin Endocrinol (Oxf) 2000, 53: 755–8.

    Article  CAS  Google Scholar 

  18. Shepherd JJ, Senator GB. Regression of liver metastases in patient with gastrin-secreting tumour treated with SMS 201-995. Lancet 1986, 2: 574.

    Article  CAS  PubMed  Google Scholar 

  19. Granberg D, Jacobsson H, Oberg K, Gustavsson J, Lehtihet M. Regression of a large malignant gastrinoma on treatment with Sandostatin LAR: a case report. Digestion 2008, 77: 92–5.

    Article  PubMed  Google Scholar 

  20. Rinke A, Müller HH, Schade-Brittinger C, et al. PROMID Study Group. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009, 27: 4656–63.

    Article  CAS  PubMed  Google Scholar 

  21. Castellano D, Salazar R, Raymond E. Future perspectives on neuroendocrine tumors. Cancer Metastasis Rev 2011, 30 (Suppl): 35–40.

    Article  PubMed  Google Scholar 

  22. Eriksson B, Renstrup J, Imam H, Oberg K. High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumours: clinical and biological effects. Ann Oncol 1997, 8: 1041–4.

    Article  CAS  PubMed  Google Scholar 

  23. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45: 228–47.

    Article  CAS  PubMed  Google Scholar 

  24. Bosman FT, Carneiro F, Hruban RH, Theise ND (eds). WHO Classification of tumours of the digestive system. Lyon: IARC Press, 2010.

    Google Scholar 

  25. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC (eds). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press, 2004.

    Google Scholar 

  26. Bajetta E, Procopio G, Catena L, et al. Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study. Cancer 2006, 107: 2474–81.

    Article  CAS  PubMed  Google Scholar 

  27. Arnold R, Wilke A, Rinke A, et al. Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors. Clin Gastroenterol Hepatol 2008, 6: 820–7.

    Article  CAS  PubMed  Google Scholar 

  28. Ducreux M, Ruszniewski P, Chayvialle JA, et al. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol 2000, 95: 3276–81.

    Article  CAS  PubMed  Google Scholar 

  29. Ruszniewski P, Ish-Shalom S, Wymenga M, et al. Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology 2004, 80: 244–51.

    Article  CAS  PubMed  Google Scholar 

  30. Aparicio T, Ducreux M, Baudin E, et al. Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur J Cancer 2001, 37: 1014–9.

    Article  CAS  PubMed  Google Scholar 

  31. Leong WL, Pasieka JL. Regression of metastatic carcinoid tumors with octreotide therapy: two case reports and a review of the literature. J Surg Oncol 2002, 79: 180–7.

    Article  PubMed  Google Scholar 

  32. Bondanelli M, Ambrosio MR, Zatelli MC, Cavazzini L, Al Jandali Rifa’y L, degli Uberti EC. Regression of liver metastases of occult carcinoid tumor with slow release lanreotide therapy. World J Gastroenterol 2005, 11: 2041–4.

    PubMed  Google Scholar 

  33. Giustina A, Bonadonna S, Bugari G, et al. High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. Eur J Endocrinol 2009, 161: 331–8.

    Article  CAS  PubMed  Google Scholar 

  34. Wuster C, Both S, Cordes U, Omran W, Reisch R. Primary treatment of acromegaly with high-dose lanreotide: a case series. J Med Case Reports 2010, 4: 85.

    Article  PubMed Central  Google Scholar 

  35. Welin SV, Janson ET, Sundin A, et al. High-dose treatment with a long acting somatostatin analogue in patients with advanced midgut carcinoid tumours. Eur J Endocrinol 2004, 151: 107–12.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Endocrinology, Catholic University, Policlinico Universitario “A. Gemelli”, Largo A. Gemelli 8, 00168, Rome, Italy

    A. Bianchi MD, L. De Marinis, A. Fusco, F. Lugli, L. Tartaglione, D. Milardi, M. Mormando, A. P. Lassandro, R. Paragliola, C. A. Rota, S. Della Casa, S. M. Corsello & A. Pontecorvi

  2. Department of Bioimaging and Radiological Sciences, Catholic University, Policlinico “A. Gemelli”, Rome, Italy

    M. G. Brizi

Authors
  1. A. Bianchi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. De Marinis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Fusco
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F. Lugli
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L. Tartaglione
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D. Milardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. Mormando
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A. P. Lassandro
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. R. Paragliola
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. C. A. Rota
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. S. Della Casa
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. S. M. Corsello
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. M. G. Brizi
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. A. Pontecorvi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Bianchi MD.

Additional information

Antonio Bianchi and Laura De Marinis contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bianchi, A., De Marinis, L., Fusco, A. et al. The treatment of neuroendocrine tumors with long-acting somatostatin analogs: A single center experience with lanreotide autogel. J Endocrinol Invest 34, 692–697 (2011). https://doi.org/10.3275/8058

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.3275/8058

Key-words

Search

Navigation